Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
FranceIPO:
10 February 2021Website:
http://www.biophytis.comNext earnings report:
N/ALast dividends:
N/ANext dividends:
N/APrice
regular market | Thu, 27 Jun 2024 13:30:00 GMTDividend
Analysts recommendations
Institutional Ownership
BPTS Latest News
PARIS, FRANCE AND CAMBRIDGE, MA / ACCESSWIRE / July 1, 2024 / Biophytis SA (Euronext Growth Paris : ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specialized in the development of therapeutics for age-related diseases, presented the roll-out and results of its phase 2/3 COVA study in the treatment of severe forms of Covid-19 at the 6th edition of the World Congress on Infectious Diseases, held from June 24 to 26, 2024 in Paris, France. Professor Valerie Pourcher MD, PhD, Chaiman of the Infectious Diseases department at Pitié Salpetriere, presented the COVAphase 2/3 clincial study results in a context where the number of Covid cases rises again.
Biophytis to receive upfront and milestones payments for a total amount up to €108 million, as well as double-digit royaltieson future sales of the product Agreement covers commercialization of BIO101 in Latin America Biophytis and Blanver intend to collaborate on manufacturing and joint clinical development for Latin America PARIS, FRANCE AND CAMBRIDGE, MA / ACCESSWIRE / June 20, 2024 / Biophytis SA (Euronext Growth Paris:ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specialized in thedevelopment oftherapeutics for age-related diseases, today announces the signature of an exclusive license agreement with Blanver, one of the leading and most trusted pharmaceutical company in Brazil, for BIO101 (20-Hydroxyecdysone) in Latin American including, but not limited to Brazil, Mexico, Argentina and Colombia. The agreement provides that Blanver will be responsible for the registration, marketing and commercialization of BIO 101 (20-Hydroxyecdysone) in its various indications: obesity, respiratory infections due to Covid-19, sarcopenia and Duchenne Muscular Dystrophy (DMD) - once Biophytis has successfully completed the planned clinical development programmes for its drug candidate.
Important note: Biophytis has set up financing in the form of Bonds redeemable in cash and in new and existing shares (ORNANE) with the company Atlas, which, after having received the shares resulting from the conversion or exercise of these instruments, is not intended to remain a shareholder of the company. The shares resulting from the conversion of the above-mentioned securities will, in general, be sold on the market very quickly, which may create downward pressure on the share price.
PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / June 10, 2024 / Biophytis SA (Euronext Growth Paris:ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specialized in the development of therapeutics for age-related diseases, today announces that it has submitted an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) regarding its phase 2 OBA clinical study in obesity with BIO101 (20-hydroxyecdysone). The OBA study will assess the efficacy and safety of BIO101 (20-hydroxyecdysone) in patients with obesity and overweight patients with secondary comorbidities, treated for 21 weeks with GLP-1 receptor agonists (GLP-1 RAs) and undergoing hypocaloric dieting.
Biophytis (BPTS) experiences a rise in after-market trading following the announcement of a new clinical development program for its investigational candidate, BIO101, aimed at treating obesity in conjunction with GLP-1 drugs.
Biophytis (NASDAQ: BPTS) shares are surging on Tuesday following the release of its earnings report for the full year of 2023. As a clinical-stage biotechnology company, Biophytis did not generate any revenue in 2023.
Biophytis (BPTS) gains on signing a partnership with Skyepharma, for the production of regulatory batches of its lead candidate, Sarconeos (BIO101).
Shares of Biophytis (NASDAQ:BPTS, EPA:ALBPS), a clinical-stage biotechnology firm, soared 41% in premarket trading on Nasdaq following the announcement of a strategic partnership with Skyepharma (LSE:SKP). The collaboration aims to produce regulatory batches of Sarconeos (BIO101), a therapeutic candidate for severe forms of Covid-19.
Biophytis (NASDAQ: BPTS ) stock is rising higher on Monday after the company announced a Sarconeos production agreement. According to a press release from Biophytis, the company reached an agreement with Skyepharma for the manufacturing of Sarconeos.
PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / September 4, 2023 / Biophytis SA (Nasdaq CM:BPTS, Euronext Growth Paris:ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specialized in the development of therapeutics that are aimed at slowing the degenerative processes associated with aging and improving functional outcomes for patients suffering from age-related diseases, including severe respiratory failure in patients suffering from COVID-19, announces that its CEO, Stanislas Veillet, will participate and hold a presentation at the "H.C. Wainwright 25th Annual Global Investment Conference", which takes place from September 11 to 13, 2023 in New York.
What type of business is Biophytis SA?
Biophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases. Its therapeutics focuses on targeting and activating key biological resilience pathways that could protect against and counteract the effects of the multiple biological and environmental stresses that lead to age-related diseases. The company's lead drug candidate is Sarconeos (BIO101), an orally administered small molecule in development for the treatment of neuromuscular diseases, including sarcopenia and Duchenne muscular dystrophy (DMD), as well as in Phase 2/3 clinical study for the treatment of severe respiratory failure in patients suffering from COVID-19. It also develops Macuneos (BIO201), an orally administered small molecule for the treatment of retinal diseases, including dry age-related macular degeneration (AMD) and Stargardt disease. Biophytis SA has a collaboration agreement with AFM-Telethon for the development of its Sarconeos (BIO101) for the treatment of DMD. The company was incorporated in 2006 and is headquartered in Paris, France.
What sector is Biophytis SA in?
Biophytis SA is in the Healthcare sector
What industry is Biophytis SA in?
Biophytis SA is in the Biotechnology industry
What country is Biophytis SA from?
Biophytis SA is headquartered in France
When did Biophytis SA go public?
Biophytis SA initial public offering (IPO) was on 10 February 2021
What is Biophytis SA website?
https://www.biophytis.com
Is Biophytis SA in the S&P 500?
No, Biophytis SA is not included in the S&P 500 index
Is Biophytis SA in the NASDAQ 100?
No, Biophytis SA is not included in the NASDAQ 100 index
Is Biophytis SA in the Dow Jones?
No, Biophytis SA is not included in the Dow Jones index
When does Biophytis SA report earnings?
Next earnings report date is not announced yet